Clinical, Cosmetic and Investigational Dermatology
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Management of superficial basal cell carcinoma: focus on imiquimod
(16137) Total Article Views
Authors: Beverly Raasch
Published Date June 2009
Volume 2009:2 Pages 65 - 75
Skin Cancer Research Group, North Queensland Centre for Cancer Research, James Cook University, Queensland, Australia
Abstract: Superficial basal cell carcinoma comprise up to 25% of all histological sub-types. They are more likely to occur on younger persons and females and although generally more common on the trunk, also occur frequently on the exposed areas of the head and neck especially in areas of high sun exposure. In the last decade, new treatment options such as topical applications that modify the immune response have been trialed for effectiveness in treating these lesions. Imiquimod 5% cream has been shown to stimulate the innate and cell mediated immune system. The short-term success of imiquimod 5% cream in randomized controlled trials comparing different treatment regimes and dosing as a treatment for small superficial basal cell carcinoma (BCC) not on the face or neck is in the range of 82% for 5 times per week application. A high proportion of participants with good response rates to topical treatment (58%–92%) experience local side effects such as itching and burning, less commonly erosion and ulceration, but the proportion of participants ceasing treatment has not been high. To date one long-term study indicates a treatment success rate of 78%–81% and that initial response is a predictor of long-term outcome. Recurrences tend to occur within the first year after treatment. Future research will compare this preparation to the gold standard treatment for superficial BCC – surgical excision.
Keywords: superficial basal cell carcinoma, imiquimod, skin cancer
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS) is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- MLA'14 -
May 16–21, 2014
- Sebusuppressive efficacy of the antioxidant bis-ethylhexyl hydroxydimethoxy benzylmalonate in the treatment of oily and blemished skin
- Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology
- Treatment of cellulite based on the hypothesis of a novel physiopathology
- Filament formation associated with spirochetal infection: a comparative approach to Morgellons disease